Wachovia initiates coverage on Cardiome Pharma (Nasdaq: CRME) with an Outperform rating and an $11-$13 valuation range.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE